| Detection and evaluation of dyslipoproteinemia. | |
| | |
MedLine Citation:
|
PMID: 9785055 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The National Cholesterol Education Program Adult Treatment Panel II guidelines recommend that all adults 20 years of age and older undergo testing to detect dyslipoproteinemia. Clinical trials have proven conclusively that lowering levels of low-density lipoprotein (LDL) cholesterol reduces coronary heart disease (CHD) incidence and mortality and total mortality in patients with and without CHD. There is persuasive scientific evidence to include young adults, women, and the elderly in the recommendation for cholesterol management. In adult without CHD, testing can begin with measurement of total cholesterol (TC) and high-density lipoprotein (HDL) cholesterol in the nonfasting state, and the results can then be used to determine which individuals require a fasting lipoprotein analysis (total cholesterol, HDL, triglycerides, and estimation of LDL); patients with known CHD should begin with lipoprotein analysis. The level of LDL cholesterol and the presence or absence of other CHD risk factors determine the need for cholesterol-lowering therapy. Patients with known CHD are at highest risk for a CHD event and have the lowest LDL cholesterol goal (100 mg/dL); patients without CHD but with elevated LDL-C (130 mg/dL) and two or more other CHD risk factors are at high risk for developing CHD and have an LDL cholesterol goal of less than 130 mg/dL; patients free of CHD with high LDL cholesterol (160 mg/dL) but fewer than two other risk factors have a lower CHD risk and an LDL cholesterol goal of less than 160 mg/dL. Elevated triglyceride may be a marker for other factors that increase CHD risk. Raising HDL cholesterol, while not proven to be of benefit, is reasonable in patients at high CHD risk. |
| | |
Authors:
|
J I Cleeman |
Related Documents
:
|
3606725 - Effects of pure capsaicinoids (capsaicin and dihydrocapsaicin) on plasma lipid and lipo... 7860745 - Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnical... 8420235 - Rationale and design of the department of veterans affairs high-density lipoprotein cho... 3063505 - Effects of acebutolol on the serum lipid profile. 21295945 - Effect of micellar lipids, dietary fiber and β-carotene on lutein bioavailability in a... 16000235 - The plant lignans matairesinol and secoisolariciresinol administered to min mice do not... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Endocrinology and metabolism clinics of North America Volume: 27 ISSN: 0889-8529 ISO Abbreviation: Endocrinol. Metab. Clin. North Am. Publication Date: 1998 Sep |
Date Detail:
|
Created Date: 1998-12-11 Completed Date: 1998-12-11 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8800104 Medline TA: Endocrinol Metab Clin North Am Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 597-611, ix Citation Subset: IM |
Affiliation:
|
National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Cholesterol / blood Cholesterol, LDL / blood Coronary Disease / blood, etiology, prevention & control Female Humans Hyperlipoproteinemias / complications, diagnosis*, therapy Hypertriglyceridemia / complications Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, LDL; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical trials of reducing low-density lipoprotein concentrations.
Next Document: Dyslipoproteinemia and diabetes.